KTRA
- · NASDAQ
- Sector -
- Industry -
- Website kintara.com
- Employees(FY) 2
- ISIN -
Performance
-
1W
-
1M
-
3M
-
6M
-
YTD
-
1Y
Profile
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Recent News & Updates
- 2024-10-17 04:35
- 2024-10-16 00:54
- 2024-10-15 23:58
- 2024-10-15 04:15
- 2024-10-13 20:30
- 2024-10-08 19:28
- 2024-10-07 19:00
- 2024-09-19 21:25
- 2024-09-17 20:30
- 2024-09-10 20:30
- 2024-09-08 20:30
- 2024-08-18 21:00
- 2024-07-07 18:30
- 2024-06-30 20:35
- 2024-06-20 19:52
- 2024-06-02 20:35
- 2024-05-29 19:47
- 2024-05-19 19:36
- 2024-05-14 10:53
- 2024-05-14 04:45
- 2024-04-03 22:38
- 2024-04-02 21:46
Why Is Kintara Therapeutics (KTRA) Stock Up 103% Today?(Investorplace)
- 2024-04-02 19:00
- 2024-03-26 21:00
- 2024-02-14 03:07
- 2024-02-11 20:00
- 2023-12-06 20:00
- 2023-12-04 20:00
- 2023-11-13 03:10
- 2023-10-30 20:00
Page 1 of 5
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.